Q-omics provides the consensus-scored DHODH profile across patient tissues and cancer cell-line models. DHODH expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DHODH is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, DHODH RNA expression shows 19,920 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where DHODH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHODH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHODH survival associations across molecular data types. DHODH RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHODH RNA expression–survival associations across cancer types. High DHODH expression shows unfavorable associations in BLCA and LGG, but favorable associations in MESO, THYM, UCS and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DHODH RNA expression.
This table summarizes DHODH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DHODH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHODH shows lower tumor expression in THCA, KICH and LIHC and higher tumor expression in COAD, KIRC and HNSC. The COAD box plot shows higher DHODH RNA expression in tumor versus normal tissue (log2 FC = +1.007, t-test p < 0.001).
This table shows molecular features associated with DHODH in patient tissues and cancer cell lines. In patient samples, DHODH shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHODH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
